|
|
Prepublished online as a Blood First Edition Paper on September 12, 2002; DOI 10.1182/blood-2002-05-1451.
 Previous Article | Table of Contents | Next Article 
Blood, 15 January 2003, Vol. 101, No. 2, pp. 473-475
CLINICAL OBSERVATIONS, INTERVENTIONS, AND THERAPEUTIC TRIALS
Brief report
Dose escalation of imatinib mesylate can overcome resistance to
standard-dose therapy in patients with chronic myelogenous
leukemia
Hagop M. Kantarjian,
Moshe Talpaz,
Susan O'Brien,
Francis Giles,
Guillermo Garcia-Manero,
Stefan Faderl,
Deborah Thomas,
Jianqin Shan,
Mary Beth Rios, and
Jorge Cortes
From the Departments of Leukemia and Bioimmunotherapy,
University of Texas M. D. Anderson Cancer Center, Houston, TX.
We investigated whether increasing the dose of imatinib mesylate
might overcome drug resistance in patients with Philadelphia chromosome-positive (Ph+) chronic myelogenous
leukemia (CML) whose disease manifests relapse or refractoriness to
therapy. Fifty-four patients with Ph+ CML in chronic phase
and with hematologic or cytogenetic resistance or relapse on imatinib
mesylate therapy at 400 mg orally daily were treated with a
higher dose of 400 mg orally twice daily (800 mg daily, 47 patients; or
600 mg daily increased from 300 mg daily, 7 patients). Among 20 patients treated for hematologic resistance or relapse, 13 (65%)
achieved a complete (n = 9) or partial (n = 4) hematologic
response, but only 1 had a cytogenetic partial response (Ph
reduction from 100% to 10%) and 1 had a minor response (Ph reduction
from 100% to 50%). Among 34 patients treated for cytogenetic
resistance or relapse, 19 (56%) achieved a complete (n = 6) or
partial (n = 7) cytogenetic response. We conclude that higher doses
of imatinib mesylate may overcome disease-poor response to
conventional doses and that this approach deserves further evaluation as frontline therapy for newly diagnosed CML.
 CiteULike  Connotea  Del.icio.us  Digg  Reddit  Technorati What's this?
Related Letter in Blood Online:
-
Transient benefit only from increasing the imatinib dose in CML patients who do not achieve complete cytogenetic remissions on conventional doses
- David Marin, John M. Goldman, Eduardo Olavarria, Jane F. Apperley, Jorge Cortes, and Hagop Kantarjian
Blood 2003 102: 2702-2703.
[Full Text]
[PDF]
This article has been cited by other articles:
|
|
|
|
 
M. Baccarani, G. Rosti, F. Castagnetti, I. Haznedaroglu, K. Porkka, E. Abruzzese, G. Alimena, H. Ehrencrona, H. Hjorth-Hansen, V. Kairisto, et al.
Comparison of imatinib 400 mg and 800 mg daily in the front-line treatment of high-risk, Philadelphia-positive chronic myeloid leukemia: a European LeukemiaNet Study
Blood,
May 7, 2009;
113(19):
4497 - 4504.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
T. Tyler
Once-Daily Dasatinib for Treatment of Patients with Chronic Myeloid Leukemia
Ann. Pharmacother.,
May 1, 2009;
43(5):
920 - 927.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
F. Castagnetti, F. Palandri, M. Amabile, N. Testoni, S. Luatti, S. Soverini, I. Iacobucci, M. Breccia, G. Rege Cambrin, F. Stagno, et al.
Results of high-dose imatinib mesylate in intermediate Sokal risk chronic myeloid leukemia patients in early chronic phase: a phase 2 trial of the GIMEMA CML Working Party
Blood,
April 9, 2009;
113(15):
3428 - 3434.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
E. Jabbour, H. M. Kantarjian, D. Jones, J. Shan, S. O'Brien, N. Reddy, W. G. Wierda, S. Faderl, G. Garcia-Manero, S. Verstovsek, et al.
Imatinib mesylate dose escalation is associated with durable responses in patients with chronic myeloid leukemia after cytogenetic failure on standard-dose imatinib therapy
Blood,
March 5, 2009;
113(10):
2154 - 2160.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
E. Jabbour, J. E. Cortes, and H. M. Kantarjian
Suboptimal Response to or Failure of Imatinib Treatment for Chronic Myeloid Leukemia: What Is the Optimal Strategy?
Mayo Clin. Proc.,
February 1, 2009;
84(2):
161 - 169.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
P. Ramirez and J. F. DiPersio
Therapy Options in Imatinib Failures
Oncologist,
April 1, 2008;
13(4):
424 - 434.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
B. C. Cho and J. H. Kim
In Reply
J. Clin. Oncol.,
March 1, 2008;
26(7):
1184 - 1186.
[Full Text]
[PDF]
|
|
|
|
|
|
|
H. M Marshall and J. M Hammond
Treatment Options in Imatinib-Resistant Chronic Myelogenous Leukemia
Ann. Pharmacother.,
February 1, 2008;
42(2):
259 - 264.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
M. Brave, V. Goodman, E. Kaminskas, A. Farrell, W. Timmer, S. Pope, R. Harapanhalli, H. Saber, D. Morse, J. Bullock, et al.
Sprycel for Chronic Myeloid Leukemia and Philadelphia Chromosome-Positive Acute Lymphoblastic Leukemia Resistant to or Intolerant of Imatinib Mesylate
Clin. Cancer Res.,
January 15, 2008;
14(2):
352 - 359.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
J. E. Cortes
Imatinib and Beyond--Therapy of CML in 2008
ASCO Educational Book,
January 1, 2008;
2008(1):
307 - 312.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
D. Frame
New strategies in controlling drug resistance in chronic myeloid leukemia
Am. J. Health Syst. Pharm.,
December 15, 2007;
64(24_Supplement_15):
S16 - S21.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
D. L. White, V. A. Saunders, P. Dang, J. Engler, A. Venables, S. Zrim, A. Zannettino, K. Lynch, P. W. Manley, and T. Hughes
Most CML patients who have a suboptimal response to imatinib have low OCT-1 activity: higher doses of imatinib may overcome the negative impact of low OCT-1 activity
Blood,
December 1, 2007;
110(12):
4064 - 4072.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
J. M. Goldman
How I treat chronic myeloid leukemia in the imatinib era
Blood,
October 15, 2007;
110(8):
2828 - 2837.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
H. Kantarjian, R. Pasquini, N. Hamerschlak, P. Rousselot, J. Holowiecki, S. Jootar, T. Robak, N. Khoroshko, T. Masszi, A. Skotnicki, et al.
Dasatinib or high-dose imatinib for chronic-phase chronic myeloid leukemia after failure of first-line imatinib: a randomized phase 2 trial
Blood,
June 15, 2007;
109(12):
5143 - 5150.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
F. Guilhot, J. Apperley, D.-W. Kim, E. O. Bullorsky, M. Baccarani, G. J. Roboz, S. Amadori, C. A. de Souza, J. H. Lipton, A. Hochhaus, et al.
Dasatinib induces significant hematologic and cytogenetic responses in patients with imatinib-resistant or -intolerant chronic myeloid leukemia in accelerated phase
Blood,
May 15, 2007;
109(10):
4143 - 4150.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
B. Chabner
Phase II Cancer Trials: Out of Control?
Clin. Cancer Res.,
April 15, 2007;
13(8):
2307 - 2308.
[Full Text]
[PDF]
|
|
|
|
|
|
|
S. Picard, K. Titier, G. Etienne, E. Teilhet, D. Ducint, M.-A. Bernard, R. Lassalle, G. Marit, J. Reiffers, B. Begaud, et al.
Trough imatinib plasma levels are associated with both cytogenetic and molecular responses to standard-dose imatinib in chronic myeloid leukemia
Blood,
April 15, 2007;
109(8):
3496 - 3499.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
M. Baccarani, G. Saglio, J. Goldman, A. Hochhaus, B. Simonsson, F. Appelbaum, J. Apperley, F. Cervantes, J. Cortes, M. Deininger, et al.
Evolving concepts in the management of chronic myeloid leukemia: recommendations from an expert panel on behalf of the European LeukemiaNet
Blood,
September 15, 2006;
108(6):
1809 - 1820.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
T. Hughes
ABL Kinase Inhibitor Therapy for CML: Baseline Assessments and Response Monitoring
Hematology,
January 1, 2006;
2006(1):
211 - 218.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
M. Golemovic, S. Verstovsek, F. Giles, J. Cortes, T. Manshouri, P. W. Manley, J. Mestan, M. Dugan, L. Alland, J. D. Griffin, et al.
AMN107, a Novel Aminopyrimidine Inhibitor of Bcr-Abl, Has In vitro Activity against Imatinib-Resistant Chronic Myeloid Leukemia
Clin. Cancer Res.,
July 1, 2005;
11(13):
4941 - 4947.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
M. Deininger, E. Buchdunger, and B. J. Druker
The development of imatinib as a therapeutic agent for chronic myeloid leukemia
Blood,
April 1, 2005;
105(7):
2640 - 2653.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
N. P. Shah
Loss of Response to Imatinib: Mechanisms and Management
Hematology,
January 1, 2005;
2005(1):
183 - 187.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
H. M. Kantarjian, J. E. Cortes, S. O'Brien, R. Luthra, F. Giles, S. Verstovsek, S. Faderl, D. Thomas, G. Garcia-Manero, M. B. Rios, et al.
Long-term survival benefit and improved complete cytogenetic and molecular response rates with imatinib mesylate in Philadelphia chromosome-positive chronic-phase chronic myeloid leukemia after failure of interferon-{alpha}
Blood,
October 1, 2004;
104(7):
1979 - 1988.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
J. P. Radich
Targeting ALL leukemia
Blood,
September 1, 2004;
104(5):
1235 - 1236.
[Full Text]
[PDF]
|
|
|
|
|
|
|
M. Harata, Y. Soda, K. Tani, J. Ooi, T. Takizawa, M. Chen, Y. Bai, K. Izawa, S. Kobayashi, A. Tomonari, et al.
CD19-targeting liposomes containing imatinib efficiently kill Philadelphia chromosome-positive acute lymphoblastic leukemia cells
Blood,
September 1, 2004;
104(5):
1442 - 1449.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
R. M. Stone
Optimizing Treatment of Chronic Myeloid Leukemia: A Rational Approach
Oncologist,
June 1, 2004;
9(3):
259 - 270.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
F. Guilhot
Indications for Imatinib Mesylate Therapy and Clinical Management
Oncologist,
June 1, 2004;
9(3):
271 - 281.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
H. Kantarjian, M. Talpaz, S. O'Brien, G. Garcia-Manero, S. Verstovsek, F. Giles, M. B. Rios, J. Shan, L. Letvak, D. Thomas, et al.
High-dose imatinib mesylate therapy in newly diagnosed Philadelphia chromosome-positive chronic phase chronic myeloid leukemia
Blood,
April 15, 2004;
103(8):
2873 - 2878.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
M. E. O'Dwyer, M. J. Mauro, C. Blasdel, M. Farnsworth, G. Kurilik, Y.-C. Hsieh, M. Mori, and B. J. Druker
Clonal evolution and lack of cytogenetic response are adverse prognostic factors for hematologic relapse of chronic phase CML patients treated with imatinib mesylate
Blood,
January 15, 2004;
103(2):
451 - 455.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
S. O'Brien, A. Tefferi, and P. Valent
Chronic Myelogenous Leukemia and Myeloproliferative Disease
Hematology,
January 1, 2004;
2004(1):
146 - 162.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
D. Marin, J. M. Goldman, E. Olavarria, J. F. Apperley, J. Cortes, and H. Kantarjian
Transient benefit only from increasing the imatinib dose in CML patients who do not achieve complete cytogenetic remissions on conventional doses
Blood,
October 1, 2003;
102(7):
2702 - 2703.
[Full Text]
[PDF]
|
|
|
|
|
|
|
J. A. Zonder, P. Pemberton, H. Brandt, A. N. Mohamed, and C. A. Schiffer
The Effect of Dose Increase of Imatinib Mesylate in Patients with Chronic or Accelerated Phase Chronic Myelogenous Leukemia with Inadequate Hematologic or Cytogenetic Response to Initial Treatment
Clin. Cancer Res.,
June 1, 2003;
9(6):
2092 - 2097.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
G. Marcucci, D. Perrotti, and M. A. Caligiuri
Understanding the Molecular Basis of Imatinib Mesylate Therapy in Chronic Myelogenous Leukemia and the Related Mechanisms of Resistance: Commentary re: A. N. Mohamed et al., The Effect of Imatinib Mesylate on Patients with Philadelphia Chromosome-positive Chronic Myeloid Leukemia with Secondary Chromosomal Aberrations. Clin. Cancer Res., 9: 1333-1337, 2003.
Clin. Cancer Res.,
April 1, 2003;
9(4):
1248 - 1252.
[Full Text]
[PDF]
|
|
|
|
|
|
|
J. V. Melo, T. P. Hughes, and J. F. Apperley
Chronic Myeloid Leukemia
Hematology,
January 1, 2003;
2003(1):
132 - 152.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
